A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Clinical trial NCT06452277 · RECRUITING

Trial details

NCT number: NCT06452277
Sponsor: Bayer
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Non-small Cell Lung Cancer, HER2 Mutation

Start date: 2024-08-28
Primary completion: 2027-10-28
Enrollment: 444

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.